| Date | Title | Description | Source |
| 23.04.2024 | Seamless Therapeutics Announces New CEO and Board Chairman t... | DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)-- Seamless Therapeutics today announced the... | forbion.co... |
| 19.04.2024 | Notice of Annual General Meeting in BioArctic AB (publ) | Notice of Annual General Meeting in BioArctic AB (publ)
Fri, Apr 19, 2024 08:00 CET Report this cont... | news.cisio... |
| 16.04.2024 | The Nomination Committee's proposal for the election of Boar... | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board i... | news.cisio... |
| 12.03.2024 | ADHD medication linked to reduced mortality | ADHD medication linked to reduced mortality
Tue, Mar 12, 2024 17:00 CET Report this content
Research... | news.cisio... |
| 06.03.2024 | Short Bowel Syndrome (SBS) Market Projected to Surge to $5.7... | - | globenewsw... |
| 27.09.2019 | How To Spot A Synthetic Biology Unicorn | Biotech is projected to reach $775 billion by 2024, but dozens of companies in the field of ... [+] ... | forbes.com... |
| 23.08.2018 | Shire wins a blockbuster OK for pipeline star lanadelumab,... | The FDA wasted no time in stamping their quick approval on Shire’s marketing application for... | endpts.com... |
| 26.05.2017 | BioCryst gets a big boost from its latest HAE data, but it... | Jon Stonehouse
A little more than a year ago, shares of Research Triangle Park, NC-based BioCry... | endpts.com... |
| 19.04.2017 | Figure 1, a knowledge-sharing app for doctors, launches spon... | Since its launch in 2013, Figure 1, a photo- and knowledge-sharing app for medical professionals, ha... | techcrunch... |
| 03.08.2015 | Morning Read: Shire gets late stage eye treatment with $300M... | Concerns over hacking medical devices have resurfaced. This time the FDA has issued a safety alert t... | medcitynew... |
| 23.07.2015 | Startups: Shire on the lookout for rare disease acquisitions | Irish pharma giant Shire is seeking out new acquisitions, despite the fact that valuations are swell... | medcitynew... |
| 17.08.2014 | Rady: From zero to 70 startups in 10 years | Ciara Kennedy was a program manager at biotechnology firm Biogen Idec in 2003 when she decided to ad... | sandiegoun... |
| 30.06.2014 | Bid target Shire gets $416m tax windfall boost | | cityam.com... |
| 31.03.2014 | More research hospitals’ tech transfer offices are now busin... | “It’s less of a traditional tech transfer approach, where you start with intellectual property that’... | medcitynew... |
| 20.01.2014 | Shire ditches troubled Dermagraft skin substitute | Regenerative therapies maker Shire (NSDQ:SHPGY) announced that it sold its troubled Dermagraft busin... | massdevice... |
| 11.11.2013 | Shire expands with $4.2bn acquisition of rare disease specia... | | cityam.com... |
| 06.05.2013 | NeuroPhage Pharmaceuticals Raises $6.4M in Equity Financing | NeuroPhage Pharmaceuticals, Inc., a Cambridge, MA-based developer of therapies for neurodegenerative... | finsmes.co... |
| 09.04.2013 | Rare disease survey: Physician-patient networks could cut do... | Among the reasons why it takes so long to diagnose a rare disease are, not surprisingly, they occur ... | medcitynew... |
| 17.12.2012 | Naurex Raises $38M in Series B Financing | Naurex Inc., an Evanston, Illinois-based clinical-stage company focused on psychiatry and neurology,... | finsmes.co... |
| 03.12.2012 | ArmaGen Technologies Raises $17M in Series A Funding | ArmaGen Technologies, a Santa Monica, CA-based developer of brain-penetrating recombinant protein th... | finsmes.co... |
| 27.07.2012 | Fundraising: Gene therapy firm targeting sickle cell anemia ... | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenole... | medcitynew... |
| 05.07.2012 | Pitches unplugged: Startup developing iPad app to determine ... | But the company’s primary interest is advancing ownership of a diabetes model for which it plans to ... | medcitynew... |
| 12.04.2012 | Shire’s asset acquisition to boost Regenerative Medicine Div... | Vascugel is designed to alleviate complications that can be caused by establishing an arteriovenous ... | medcitynew... |
| 28.03.2012 | Promethera Biosciences Raises €23.6M in Series B Funding | Promethera Biosciences, a Mont-Saint-Guibert, Belgium-based cell therapy company operating in the fi... | finsmes.co... |
| 06.03.2012 | Diabetic foot ulcer treatment gets green light for phase 3 t... | The Princeton, New Jersey-based company, citing data from Susquehanna Research, said diabetic foot u... | medcitynew... |
| 08.02.2012 | Success or withdrawal hang in balance for Shire blood pressu... | Although the Irish pharmaceutical company, which has U.S. headquarters in the Philadelphia area, no ... | medcitynew... |
| 07.02.2012 | Shire drug to manage ADHD symptoms in adults gets FDA approv... | The Irish company with U.S. headquarters in Philadelphia, Pennsylvania, has sought to develop other ... | medcitynew... |
| 16.12.2011 | Atlas Venture Partners with Shire to Invest in Companies Dev... | Atlas Venture, a Cambridge, Mass.-based venture capital firm, has signed a multi-year partnership wi... | finsmes.co... |
| 05.12.2011 | Shire agrees to more clinical trials for blood pressure drug... | Shire had resisted repeated requests for additional testing, arguing it had satisfied the testing re... | medcitynew... |
| 17.11.2011 | Chelsea’s Northera for Parkinson’s patients gets FDA priorit... | Northera was developed by Japanese pharmaceutical company Dainippon Sumitomo Pharma. The company’s p... | medcitynew... |
| 02.11.2011 | Lessons from a $750M exit: Advanced BioHealing VP discusses ... | Tozer said that discussions with private equity firms came close to a deal. But in the second half o... | medcitynew... |
| 25.08.2011 | Shire ditches Dermagraft for leg ulcers, just three months a... | Shire plc (NSDQ:SHPGY) became the latest firm to abandon its pursuit of a leg ulcer indication for t... | massdevice... |
| 01.03.2011 | NeuroPhage Pharmaceuticals Raises $12.4M in Series B Financi... | NeuroPhage Pharmaceuticals, Inc., a Cambridge, MA-based biotechnology company developing a protein d... | finsmes.co... |
| 02.02.2011 | Blood pressure drug misses in phase III; Chelsea aims for ne... | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently... | medcitynew... |
| 27.08.2010 | Shire Announces European Approval of VPRIV® (velaglucerase a... | Cambridge, MA, US – August, 27th 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty bi... | realwire.c... |
| 05.10.2007 | Life sciences briefing: Friday, Oct. 5, 2007 | Featured companies: Gilde Healthcare Partners, Konanda Pharma Partners, Healthvision, OrbiMed, Quova... | venturebea... |
| 18.09.2007 | Life sciences briefing: Tuesday, Sept. 18, 2007 | Featured companies: BioMicro Systems, Diasome Pharmaceuticals, FitLinxx, FitSense, Novartis, Radius ... | venturebea... |
| - | Diabetic foot ulcer treatment gets green light for phase 3 t... | U.S. regulators have agreed to phase 3 clinical trials for an advanced wound care device and drug de... | medcitynew... |
| - | Chelsea’s Northera for Parkinson’s patients gets FDA priorit... | Chelsea Therapeutics‘ (NASDAQ:CHTP) drug candidate for dizziness and fainting in Parkinson’s disease... | medcitynew... |
| - | Blood pressure drug misses in phase III; Chelsea aims for ne... | Chelsea Therapeutics is shifting gears with a drug candidate intended for Parkinson’s disease patien... | medcitynew... |
| - | Morning Read: Shire gets late stage eye treatment with $300M... | TOP STORIES
Shire has acquired Foresight Biotherapeutics in a $300 million deal. The purchase gives ... | medcitynew... |
| - | Fundraising: Gene therapy firm targeting sickle cell anemia ... | Company name: bluebird bio.
Industry: Biotechnology.
Location: Cambridge, Massachusetts.
Product: Ge... | medcitynew... |
| - | Shire agrees to more clinical trials for blood pressure drug... | One year after Shire (NASDAQ:SHPGY) pulled its drug for low blood pressure, ProAmatine, from the mar... | medcitynew... |
| - | Shire’s asset acquisition to boost Regenerative Medicine Div... | Shire (NASDAQ:SHPGY) has acquired the assets of a therapeutics firm, including a vascular surgery te... | medcitynew... |
| - | More research hospitals’ tech transfer offices are now busin... | In the same way that funding for early-stage innovations is changing, so is how those innovations ar... | medcitynew... |
| - | Pitches unplugged: Startup developing iPad app to determine ... | A medication adherence tool, an innovative lighting solution embedded in a cane and a device to meas... | medcitynew... |
| - | Shire drug to manage ADHD symptoms in adults gets FDA approv... | Shire (NASDAQ: SHPGY) has secured approval from U.S. regulators for a drug to manage symptoms of Att... | medcitynew... |
| - | Startups: Shire on the lookout for rare disease acquisitions | Irish pharma giant Shire is seeking out new acquisitions, despite the fact that valuations are swell... | medcitynew... |
| - | Lessons from a $750M exit: Advanced BioHealing VP discusses ... | Regenerative medicine company Advanced BioHealing is now part of Shire (NASDAQ:SHPGY), but before it... | medcitynew... |
| - | Success or withdrawal hang in balance for Shire blood pressu... | Shire (NASDAQ:SHPGY) has reached an agreement with U.S. regulators in the long-running saga over its... | medcitynew... |
| - | Rare disease survey: Physician-patient networks could cut do... | A new report is recommending developing more online networks as a way to shorten the more than seven... | medcitynew... |
